SCHEMBL10067372

SCHEMBL10067372

[C-]#[N+]c1ccc2[nH]c(C(C)(C)C)c(C)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KIF11 P52732 1/20 0.33
▸ KDM4E B2RXH2 5/20 0.32
▸ MAPT P10636 5/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ HSD17B10 Q99714 3/20 0.32
▸ GFER P55789 2/20 0.32
▸ ALOX15 P16050 2/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ HPGD P15428 4/20 0.32
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ TSHR P16473 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25815600 0.78 MEN1 (0.49) MEN1KMT2ANPC1RAB9AKIF11
SCHEMBL10067362 0.76 MEN1 (0.59) MEN1KMT2ANPC1RAB9AKIF11
SCHEMBL10067361 0.75 KMT2A (0.50) MEN1KMT2ANPC1RAB9AKIF11
SCHEMBL22330351 0.75 LMNA (0.50) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL10067389 0.75 LMNA (0.49) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL10067359 0.72 KDM4E (0.44) MEN1KMT2ANPC1RAB9AKIF11
SCHEMBL10067388 0.72 NPC1 (0.44) MEN1KMT2ANPC1RAB9AKIF11
SCHEMBL10082774 0.71 L3MBTL1 (0.60) MEN1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL12755286 0.70 AHR (0.57) MEN1KMT2ARAB9AKIF11MAPT
SCHEMBL13208514 0.69 IDO1 (0.44) IDO1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 MEN1 2366/4885KMT2A 377/4885NPC1 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback